3/27
08:36 am
phat
Phathom Pharmaceuticals (PHAT) was upgraded by Barclays PLC from "equal weight" to "overweight". They now have a $18.00 price target on the stock, up from $16.00.
Low
Report
Phathom Pharmaceuticals (PHAT) was upgraded by Barclays PLC from "equal weight" to "overweight". They now have a $18.00 price target on the stock, up from $16.00.
3/27
08:31 am
phat
Rating for PHAT
Low
Report
Rating for PHAT
3/27
08:31 am
phat
Rating for PHAT
Low
Report
Rating for PHAT
3/27
04:55 am
phat
Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
Medium
Report
Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
3/27
04:55 am
phat
Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
Medium
Report
Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
2/27
10:46 am
phat
Rating for PHAT
Medium
Report
Rating for PHAT
2/27
10:46 am
phat
Rating for PHAT
Medium
Report
Rating for PHAT
1/14
08:42 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.